Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer

NCT02038621 is registered in ClinicalTrials.gov with The Second People's Hospital of Sichuan as lead sponsor.

NCT NCT02038621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02038621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer
Lead sponsor
The Second People's Hospital of Sichuan
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2014
Completion date
December 31, 2017
Enrollment
224 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer